We urge Congress to capitalize on the expertise of the community health centers as part of the EHE initiative so that we can expand PrEP and PrEP-related services by increasing funding from the current $102 million to $152 million, as proposed by President Biden’s FY2022 budget.
The HIV+Hepatitis Policy Institute and others are requesting that CMS update the HCV screening National Coverage Determination to bring it in line with the 2020 U.S. Preventive Services Task Force recommendation for HCV screening. The current coverage determination only requires Medicare coverage for HCV screening of baby boomers and people at high risk. We are requesting that Medicare should cover screening of everyone between the ages of 18-79, regardless of symptoms or risk group.
We strongly support Louisiana Senate Bill 94, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum. This bill has already passed the Senate is scheduled to be voted on in the House this week. We urge you to support this critical bill for patients.
On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2022 Labor, HHS spending bill.
We strongly support Senate Bill 94, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum. This bill is scheduled to be voted on in the Senate on Monday, May 10th. We urge you to support this critical bill for patients.